Income Taxes

3 Months Ended

Jun. 30, 2011

Income Tax Disclosure [Text Block]

(13) Income Taxes

          During the three and six months ended June 30, 2011, the Company recorded $5,000 of income tax expense related to the Canadian subsidiary. During the three and six months ended June 30, 2010, the Company recorded a net income tax benefit of $0.2 million consisting principally of a Canadian transfer pricing refund. The Company did not recognize a U.S. Federal income tax provision for the first half of 2011 or 2010 because the estimated annual effective tax rate was zero. The sale of the specialty pharmaceutical business in January 2010, including the sale of in-process research and development, was a taxable transaction for federal income tax purposes, although it resulted in no federal income tax liability due to the tax basis the Company had in divested assets and the net operating loss generated in 2010. As of June 30, 2011, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not its deferred tax assets will not be realized.